An interventional study of Telehealth delivery of pharmacy PrEP/PEP and Standard pharmacy PrEP/PEP delivery in HIV, sponsored by Fred Hutchinson Cancer Center. Not yet recruiting at 1 site in Kenya. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Fred Hutchinson Cancer Center · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this study, the investigators will evaluate whether introducing a remote nurse to screen, counsel, and guide clients through HIV self-testing (via a telehealth platform) and support interested clients (via SMS) between pharmacy visits increases PrEP/PEP initiations and continuation compared to standard PrEP/PEP delivery by pharmacy providers. The investigators hypothesize that pharmacy PrEP/PEP services delivered with telehealth support will result in better service utilization and implementation outcomes compared to standard delivery and be cost-effective to implement.
Participating study pharmacies will be 1:1 randomized 24 pharmacies (n=1,580 clients ≥15 years) to either: 1) telehealth support, where a remote nurse screens, counsels, and guides clients through HIV self-testing (HIVST) and, between visits, communicates with interested clients via 2-way SMS, or 2) standard delivery, where the pharmacy provider performs all delivery tasks and clients are not given additional support. The primary outcomes are PrEP/PEP initiation and continuation, assessed 180 days following clients' first pharmacy PrEP/PEP visit.
Fred Hutchinson Cancer Center is the lead sponsor of 547 studies on the registry; 79 are open to participants now.
Of its 59 completed or terminated interventional studies of FDA-regulated products, 46 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pharmacies
Pharmacists/remote nurses
Clients
Exclusion Criteria:
Clients
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pharmacy provider-led PrEP/PEP delivery, with telehealth support from remote nurses for counseling and testing at or between pharmacy visits (includes guided HIV self-testing and optional 2-way SMS with remote nurses).
Other: Telehealth delivery of pharmacy PrEP/PEP
Pharmacy provider-led PrEP/PEP delivery, without telehealth support from remote nurses for counseling and testing at or between pharmacy visits (includes guided HIV self-testing).
Other: Standard pharmacy PrEP/PEP delivery
Remote nurses screen, counsel, and guide HIV self-testing for pharmacy clients; pharmacy providers dispense PrEP or PEP. SMS support from remote nurses available between pharmacy visits.
Pharmacy provider screen, counsel, and guide HIV self-testing for pharmacy clients, and dispense PrEP or PEP. SMS support not available between pharmacy visits.
PrEP/PEP initiation
Pharmacy-level; count outcome: # of unique clients dispensed any form of PrEP or PEP over the implementation period
Time frame: 18 months post implementation
PrEP/PEP continuation
Pharmacy-level; count outcome: # of unique clients that refilled PrEP, transitioned from PEP-to-PrEP, or were dispensed PEP or on-demand PrEP 1+ times over the implementation period
Time frame: 18 months post implementation
PrEP initiation
Pharmacy-level; count outcome: # of unique clients dispensed any form of PrEP over the implementation period
Time frame: 18 months post implementation
PEP initiation
Pharmacy-level; count outcome: # unique clients dispensed any form of PEP over the implementation period
Time frame: 18 months post implementation
PrEP/PEP use
Pharmacy-level; count outcome: # of unique clients who swallowed any PrEP or PEP during the implementation period
Time frame: 1.5 and 6 months from initiation
PrEP use
Pharmacy-level; count outcome: # of unique clients who swallowed any PrEP during the implementation period
Time frame: 1.5 and 6 months from initiation
PEP use
Pharmacy-level; count outcome: # of unique clients who swallowed any PEP during the implementation period
Time frame: 1.5 and 6 months from initiation
PrEP refill
Pharmacy-level; count outcome: # of unique clients who refilled PrEP after initiating PrEP
Time frame: 18 months post implementation
Repeat PEP
Pharmacy-level; count outcome: # unique clients who were dispensed PEP or PEP-in-pocket after initiating PEP
Time frame: 18 months post implementation
PEP-to-PrEP
Pharmacy-level; count outcome: # unique clients who were dispensed PrEP after initiating PEP (any form) over the implementation period
Time frame: 18 months post implementation
Engaged with 1+ product
Pharmacy-level; count outcome: # of unique clients that were dispensed more than one HIV prevention product (oral PrEP, injectable PrEP, PEP, etc) over the implementation period
Time frame: 18 months post implementation
On-demand PrEP use
Pharmacy-level; count outcome: # of unique clients who were dispensed and swallowed any on-demand PrEP over the implementation period
Time frame: 6 months from initiation
PEP-in-Pocket use
Pharmacy-level; count outcome: # of unique clients who were dispensed and swallowed any PEP-in-Pocket over the implementation period
Time frame: 6 months from initiation
Product choice
Individual-level; binary outcome: % of total PrEP/PEP clients that were dispensed each type of product (e.g., oral PrEP, on- demand PrEP, PEP, DVR, etc).
Time frame: 18 months post implementation
PrEP adherence
Individual-level; binary outcome: % PrEP initiators (excluding on-demand) with optimal TFV-DP concentration in DBS
Time frame: 1.5 months from initiation
Reach
Individual-level; binary outcome: % of PrEP/PEP clients in different populations of interest (e.g., men; youth \<25 years); with separate evaluations by product type
Time frame: 18 months post implementation
Efficiency
Pharmacy-level; continuous outcome: Avg. duration (per visit \& annually) of pharmacy providers' encounter per PrEP/PEP client, and clients' PrEP/PEP visit duration
Time frame: 18 months post implementation
Fidelity
Individual-level; binary outcome: % of clients that received PrEP/PEP services as intended (e.g., correct quantity of drugs)
Time frame: 1.5 months post initiation
Sustainment
Pharmacy-level; count outcome: Volume of unique PrEP/PEP clients served in the past 6 months, assessed at 24 months
Time frame: 24 months post implementation
Acceptability
Individual-level; cont, binary outcome: # of unique client who find the study components acceptable; % of providers, including remote nurses, indicating acceptability; Also assessed in Aim 2 (described below)
Time frame: 24 months post implementation
Time to use (for on-demand PrEP) at 1.5 months
Pharmacy-level; continuous outcome: Avg. duration (in days) from on-demand PrEP dispensing to use, among on-demand clients
Time frame: 1.5 months
Time to use (for on-demand PrEP) at 6 months
Pharmacy-level; continuous outcome: Avg. duration (in days) from on-demand PrEP dispensing to use, among on-demand clients
Time frame: 6 months
STI diagnosis
Individual-level; binary outcome: % of PrEP/PEP clients with a syndromic STI diagnosis (at any pharmacy PrEP/PEP visit)
Time frame: 18 months post implementation
Other drugs dispensed
Pharmacy-level; binary outcome: % of PrEP/PEP clients dispensed other drugs (e.g., hypertension, contraception) at their visit
Time frame: 18 months post implementation
HIV incidence
Pharmacy-level; binary outcome: % of PrEP/PEP clients who tested positive
Time frame: 18 months
HIV risk
Inidiviudal-level; binary outcome: % of PrEP/PEP clients reporting specific behaviors (i.e., multiple sex partners)
Time frame: 18 months post implementation
Plan to share: Yes — Participant-level pharmacy record and research data will be shared through deposition of the data in an open-access public repository (Dryad). In addition to sharing the study data publicly, data dictionaries and other tools supporting use of the data will be shared.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: De-identified pharmacy record and research data from this study will be deposited in the Dryad data repository within 12 months of publication.
Access criteria: The study data will be accessible through the Dryad data repository. For all publications, a dataset will be created that is assigned a digital object identifier (DOI), which will be referenced in the publication so the research community can easily find and access the data, if interested. The Dryad repository can also be searched by topic, institution, and investigator name, which should make it easy for other interested parties to find and access the study data. Any study data that cannot be shared via Dryad, will be made available through a formal request to the PIs. We will share data and supporting documentation upon request to outside investigators, after scientific review, IRB approval, and obtaining relevant Data Use Agreements.
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Mar 2028, 13 months later.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Feb 2027, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fred Hutchinson Cancer Center →